Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
03/2010
03/23/2010US7683038 Such as gellan, carboxymethylcellulose, pectic acid, pectin and hyaluronic acid derivativesl; for use in the pharmaceutical, biomedical, surgical and healthcare fields
03/23/2010US7683037 Myocardial perfusion imaging method
03/23/2010US7683034 Use of enzyme inhibitors of aminopeptidase N and/or dipeptidylpeptidase IV
03/23/2010US7682807 Alzheimer's disease diagnosis based on mitogen-activated protein kinase phosphorylation
03/23/2010US7682632 Tamper-resistant oral opioid agonist formulations
03/23/2010US7682608 Stabilized preparations containing antibody
03/23/2010US7682607 Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
03/23/2010CA2465686C Process for the preparation of 4-(8-chloro-5,6-dihydro-11h-benzo(5,6)-cyclohepta-(1,2b)-pyridin-11-ylidene)-1-piperidinecarboxylic acid ethyl ester (loratadine)
03/23/2010CA2460177C 3-substituted-4-pyrimidone derivatives
03/23/2010CA2397594C Ethanol solvate of (-)-cis-2-(2-chlorophenyl)-5,7-dihydroxy-8[4r-(3s-hydroxy-1-methyl)piperidinyl]-4h-1-benzopyran-4-one
03/23/2010CA2396702C N,o-amidomalonate platinum complexes
03/23/2010CA2390317C Product inhibiting transduction of g heterotrimeric protein signals combined with another anti-cancer agent for therapeutic use in cancer treatment
03/23/2010CA2389767C Quinazoline derivatives as vegf inhibitors
03/23/2010CA2380951C Pharmaceutical compositions for oral and topical administration
03/23/2010CA2378052C Use of ginkgo extract
03/23/2010CA2377278C Prodrugs of carbamate inhibitors of impdh
03/23/2010CA2358457C Topical composition comprising n-acetylaldosamines or n-acetylamino acids
03/23/2010CA2352436C Polymorphs of telmisartan, processes for preparing them and their use in the preparation of a pharmaceutical composition
03/23/2010CA2332608C Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination
03/23/2010CA2332488C Cells and animals deficient in protein kinase c epsilon
03/23/2010CA2325386C Hydrogel compositions useful for the sustained release of macromolecules and methods of making same
03/23/2010CA2309639C Small peptides and methods for treatment of asthma and inflammation
03/23/2010CA2223412C Method for prolonging the expression of a gene of interest using soluble ctla4 molecules
03/23/2010CA2209124C Antitumor agent effect enhancer containing il-6 antagonist
03/23/2010CA2203655C Tumor necrosis factor-gamma
03/18/2010WO2010030012A1 ESTERIFIED α-GALACTOSYLCERAMIDE
03/18/2010WO2010029996A1 Pharmaceutical composition
03/18/2010WO2010029938A1 Novel crystal forms of 4-(2-aminopyridin-4-yl)-3-(4–fluoro- phenyl)-1-(1,4,5,6-tetrahydro-6-oxopyridazin-3-yl)-1h-pyra-zole methanesulfonate and process for production of same
03/18/2010WO2010029021A1 Taurine or taurine-like substances for the prevention of brain oedema
03/18/2010US20100069446 L-threonine derivatives of high therapeutic index
03/18/2010US20100069386 Modulators of Hedgehog Signaling Pathways, Compositions and Uses Related Thereto
03/18/2010US20100069385 Liquid formulations of phospholipase enzyme inhibitors
03/18/2010US20100069379 Bicyclic androgen and progesterone receptor modulator compounds and methods
03/18/2010US20100069369 Kinase Inhibitors And Their Uses
03/18/2010US20100069368 Organic Compounds and Their Uses
03/18/2010US20100069359 Constrained spirocyclic compounds as cgrp receptor antagonists
03/18/2010US20100069344 Small molecule antagonists of bcl2 family proteins
03/18/2010US20100069342 Formoterol/steroid bronchodilating compositions and methods of use thereof
03/18/2010US20100068695 Inhibitor for enzyme having two divalent metal ions as active center
03/18/2010US20100068274 Process for production of tablet
03/18/2010US20100068266 Ex vivo-modifiable multiple-release state final dosage form
03/18/2010US20100068255 liposomes comprising humanized Fab fragment of monoclonal antibody that binds cell surface markers, amphipathic vesicle-forming lipid and polyethylene glycol derivatized lipid, capable of inhibiting growth and proliferation of target cells; HER growth factor receptors
03/18/2010US20100068234 Laser-Markable Compositions
03/18/2010US20100068195 recombinant human N-acetylgalactosamine-6-sulfatase (GALNS) enzyme having purity of at least about 95 , 90 % conversion of Cys at position 53 to C alpha -formylglycine, bis-phosphorylated oligomannose chains per monomeric protein chain; use in the diagnosis, prophylaxis etc.
03/18/2010US20100068191 Purified mesenchymal stem cell compositions and methods of purifying mesenchymal stem cell compositions
03/18/2010US20100068183 Methods of treating lysosomal storage related diseases by gene therapy
03/18/2010US20100068173 Recombinant Human Albumin-Interleukin-11 Fusion Protein With Long-Lasting Biological Effects
03/18/2010US20100068169 Monolithic drug delivery system
03/18/2010US20100068167 Low Salt Forms of Polyallylamine
03/18/2010US20100068166 Oral composition comprising dimethicone copolyol
03/18/2010US20100068144 Nonlinear optical detection of molecules comprising an unnatural amino acid possessing a hyperpolarizability
03/18/2010CA2736554A1 Novel crystal forms of 4-(2-aminopyridin-4-yl)-3-(4-fluorophenyl)-1-(1,4,5,6-tetrahydro-6-oxopyridazin-3-yl)-1h-pyrazole methanesulfonate and methods for their preparation
03/17/2010EP2163643A1 Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof
03/17/2010EP2163626A1 Human FGF-21 gene and gene expression products
03/17/2010EP2163561A1 NOGO receptor-mediated blockade of axonal growth
03/17/2010EP2163543A1 Nitrogen-containing heterocyclic derivative having 11 beta-hydroxysteroid dehydrogenase type i inhibitory activity
03/17/2010EP2163258A1 Preventive/remedy for cancer
03/17/2010EP2163254A1 Use of HGF for the manufacture of a medicament for treating fibrotic disorders
03/17/2010EP2163251A1 Treatment of ascites with thymus extracts
03/17/2010EP2163250A1 Anticancer therapy by transplanting vascular endothelial progenitor cells
03/17/2010EP2163247A1 USE OF NARINGENIN AND NARINGIN AS INHIBITORS FOR TRANSFORMING GROWTH FACTOR-beta1 SIGNALING PATHWAY
03/17/2010EP2163246A1 Taurine or taurine-like substances for the prevention of the irreversible visual effects of vigabatrin
03/17/2010EP2163241A1 Pharmaceutical compositions for the coordinated delivery of NSAIDs
03/17/2010EP1786810B1 Ligands for g-protein coupled receptors
03/17/2010EP1385870B1 Peptides as ns3-serine protease inhibitors of hepatitis c virus
03/17/2010EP1315502B1 Method for treating erectile dysfunction and increasing libido in men
03/17/2010CN101674841A Anti-histamine substance and method for production thereof
03/17/2010CN101674819A Use of s1p receptor modulator
03/17/2010CN101671393A Angiopoietin-2 specific binding agents
03/17/2010CN101671388A Blood brain barrier penetrable erythropoietin (EPO) and application thereof
03/17/2010CN101671335A Cytotoxins, prodrugs, linkers and stabilizers useful therefor
03/17/2010CN101671299A Method for synthesizing Nexavar
03/17/2010CN101671260A Method for preparing O-desmethyl-venlafaxine
03/17/2010CN101670060A Traditional Chinese medicine composition for treating such diseases as hepatic stagnation, chest stuffiness and distension and preparation method
03/17/2010CN101669938A Nutrient composition for eliminating exercise-induced fatigue
03/16/2010US7678918 Induce the biosynthesis of cytokines such as interferon and tumor necrosis factor; antiviral and antitumor agents
03/16/2010US7678885 Recombinant bone morphogenetic protein heterodimers, compositions and methods of use
03/16/2010US7678884 Biologically active peptide and agent containing the same
03/16/2010US7678834 Substituted 4-aminocyclohexanol compounds
03/16/2010US7678824 Methods for treatment with bucindolol based on genetic targeting
03/16/2010US7678812 Aminotetralin-derived urea modulators of vanilloid VR1 receptor
03/16/2010US7678810 activin receptor-like kinase 5 (ALK5) (which is a TGF- beta type I receptor) inhibitor ; glomerulonephritis, diabetic nephropathy, hepatic fibrosis, liver cirrhosis, pulmonary fibrosis, or alopeciarosis; hair growth stimulant
03/16/2010US7678809 Useful in the treatment of chronic and acute pain; 1-[4-dibenzocycloheptyl-4-piperidinyl]-1,3-dihydro-2H-1,3-benzamidazol-2-one;
03/16/2010US7678805 inhibitors are unable to promote death of IL-3 dependent cells cultured in presence of IL-3; non-toxic, selective and potent
03/16/2010US7678790 sulfonylurea derivatives, sulfonylthiourea derivatives, sulfonylguanidine derivatives, sulfonylcyanoguanidine derivatives, thioacylsulfonamide derivatives, and acylsulfonamide derivatives; effective for prevention and treatment of cardiovascular diseases, antithrombotic agents
03/16/2010US7678779 Methods for the administration of amifostine and related compounds
03/16/2010US7678777 increase a person immunity by oral administering a mixture including a dextran, promoting the cell growth and colonizing in the intestine of a subject without supplying L. casei subsp. casei at all times
03/16/2010US7678760 Inhibitors of Memapsin 2 and use thereof
03/16/2010US7678573 Using plug flow bioreactor system which mimics bone marrow microenvironment for propagation and maintenance of stromal cells
03/16/2010US7678372 Tyrosine kinase inhibitors; anticancer agents; genetic engineered protein
03/16/2010CA2510519C Condensed furan compounds
03/16/2010CA2396965C Piperidine- and piperazine substituted n-hydroxyformamides as inhibitors of metalloproteinases
03/16/2010CA2390590C Adenosine receptor antagonists and methods of making and using the same
03/16/2010CA2386980C Benzodiazepine derivatives for use in acute or chronic neurological disorders
03/16/2010CA2376986C Method for purification of proteins
03/16/2010CA2372575C Bradykinin receptor antagonists
03/16/2010CA2314286C Anthelmintic compositions
03/16/2010CA2274108C 2-cyclopenten-1-one and its derivatives as inhibitors of the nf-kb factor
03/16/2010CA2191577C Method for treating and preventing atherosclerosis
03/11/2010WO2010028389A1 Image-guided energy deposition for targeted drug delivery
1 ... 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 ... 1564